Novo Saved the Quarter-Lilly Still Has the Bigger Prize in GLP-1 Pills

Novo steadied sentiment, but oral GLP-1s are still reshaping the market

Novo Nordisk avoided a panic this quarter. But relief rallies can create the wrong lesson.

After more than $400 billion in market value erased from Novo's peak, investors were looking for proof that volume could outrun pricing pressure. Novo's first-quarter adjusted operating profit above expectations gave them part of that answer, which helps explain the relief trade. Still, the bigger story is whether obesity pills can broaden the patient pool enough to reopen the valuation debate for the whole category.

Lilly still has the clearest proof point

For now, Lilly's commercial lead is harder to ignore. In the first quarter, Zepbound generated $4 billion in sales versus Wegovy's $2.7 billion. That matters because it shows Lilly is not only defending share; it is winning the part of the market investors are rewarding today.

At the same time, early pill data suggest the category may be expanding rather than simply shifting between formats. Reuters reports obesity pills could expand the market to millions more patients, and analysts have made a similar point about oral treatment offering an easier route to start treatment. That is the real opportunity in front of the market.

Why pills could change adoption before they change the revenue mix

The oral format may be changing behavior before it fully changes the revenue model. Because the pill offers an easier route to start treatment, it may help capture patients who would hesitate at an injection. That lowers the initiation hurdle and gives the market a reason to treat obesity therapy as broader than a narrow, self-selecting group.

The addressable pool remains largely untapped

The expansion thesis is not just theoretical. More than 100 million Americans have obesity, and only a fraction are on GLP-1 therapies. Novo's launch adds substance to the idea that pills can reach people who might not otherwise start treatment: its Wegovy pill prescriptions have topped 3 million after about five months in the U.S., while Lilly said its own pill prescriptions were markedly higher than the 20,000 it reported roughly six weeks earlier.

Coverage optics still matter as much as demand

The next question is persistence. Starting July 1, millions of seniors with Medicare could access GLP-1 weight-loss treatment for $50 a month. That matters not just because it lowers upfront cost, but because it can make ongoing treatment look less like a luxury purchase and more like long-term disease management.

Bulls see a wider, more durable market: easier initiation, better continuation, and less damage from price cuts if the pie expands fast enough. Bears see early excitement, possible front-loading of demand, and a market still vulnerable to coverage gaps.

Watch three things now: - Whether Novo's 3 million prescriptions include enough true new starters to validate expansion rather than simple format switching. - Whether Lilly's faster-than-earlier pill growth continues to build. - Whether lower out-of-pocket cost improves persistence more than it compresses perceived value.

Access remains the weak link in an otherwise bullish story

Bulls are trading a bigger future market for a safer present market. That is understandable in a hot category, but access is still uneven, and investors may be underestimating how much obesity drugs still depend on coverage optics.

A delayed pilot still moved the stocks

Even a delayed access pilot can hit share prices. When CMS pushed back on BALANCE, Lilly closed nearly 2% lower and Novo fell 4%. If a limited pilot can move the market that much, coverage risk is still a major valuation lever.

Affordability remains a real bottleneck

Patient data reinforce that point. KFF polling finds 56% of GLP-1 users say these drugs were difficult to afford. That is a practical barrier, not just a headline risk. A category can look enormous on paper and still fall short commercially if too many patients stop after starting.

The near-term setup is still messy

The bull case still has support: the Medicare GLP-1 Bridge program has been extended through 2027, and payer resistance to BALANCE may reflect negotiation posture as much as a full retreat from coverage.

But the near-term bear case is cleaner. CMS has indefinitely postponed the pilot run of BALANCE, CVS declined to participate, and Novo is suing Lilly over allegations of deceptive advertising. That makes the obesity space more litigious and more sensitive to messaging mistakes than many investors want to admit.

The point is not that the obesity thesis is broken. It is that demand alone is not enough; access still determines how much of that demand becomes durable revenue.

Lilly still looks like the higher-upside setup

The question is no longer whether pills work. Novo has shown that. Its Wegovy pill prescriptions have topped 3 million after about five months, which is a meaningful commercial signal.

What matters now is risk/reward. Novo has provided safer proof that the oral format can gain traction. Lilly still has the more interesting setup because Zepbound already produced $4 billion in first-quarter sales versus Wegovy's $2.7 billion. If pills expand the category instead of merely dividing it, the company with the larger current base and a functioning second-growth vector is probably the one with the bigger upside.

That thesis weakens if Lilly's pill growth stalls from where it is today or if coverage friction becomes severe enough to cap utilization. Until then, Lilly still looks like the better asymmetry.